Tirzepatide Dosage Chart: What Published Sources Document
This guide explains what published FDA labels and clinical trial literature document about tirzepatide doses studied in type 2 diabetes and obesity trials. It does not provide a dosing schedule for individual use, but describes the ranges and escalation patterns reported in regulatory filings and peer-reviewed research.
What Doses of Tirzepatide Have Been Studied
According to the FDA label for Mounjaro, tirzepatide is approved at maintenance doses of 5 mg, 10 mg, and 15 mg administered once weekly by subcutaneous injection. A 2024 network meta-analysis published in BMJ involving 39,246 participants reported that tirzepatide at 15 mg induced the largest reduction in haemoglobin A1c concentrations, with a mean difference of -2.10% compared with placebo and high confidence of evidence. The same analysis found tirzepatide 15 mg the most effective GLP-1 receptor agonist drug for reducing fasting plasma glucose concentrations.
Tirzepatide doses of 5 mg, 10 mg, and 15 mg once weekly have also been evaluated in obesity trials without diabetes. A systematic review in Annals of Internal Medicine covering 26 randomized controlled trials and 15,491 participants reported that tirzepatide 15 mg once weekly resulted in weight loss of up to 17.8% after 72 weeks of therapy, compared with placebo. Lower doses were studied in the same trials, with dose-dependent effects on body weight and glycemic control documented across the 5 mg, 10 mg, and 15 mg range.
Starting Dose of Tirzepatide Reported in Trials
The FDA labels for tirzepatide do not specify a universal starting dose in the brief pharmacology sections provided, but the SURMOUNT and SURPASS trial programs, reviewed in a 2025 article in Expert Opinion on Pharmacotherapy, describe escalation protocols beginning at lower doses and increasing at intervals to reduce gastrointestinal adverse events. The same review notes that tirzepatide is approved at the same doses—5, 10, and 15 mg—for both type 2 diabetes and chronic weight management, and that the drug is well-tolerated with a safety profile similar to GLP-1 receptor agonists. Gastrointestinal adverse effects, including nausea in 28% to 44% of participants and diarrhea in 21% to 30%, were reported in a 2024 review in JAMA covering nutrient-stimulated hormone-based medications.
The specific increments and timing of dose escalation belong to the domain of prescribing decisions and are not detailed in the pharmacology abstracts available. Readers seeking a starting dose for their own use should consult a qualified clinician familiar with tirzepatide prescribing.
Tirzepatide Dosing for Weight Loss in Units
Tirzepatide doses in clinical trials and FDA-approved labeling are expressed in milligrams per injection, not in insulin syringe units. The conversion between milligrams and units depends on the concentration of the solution being used, which varies by formulation and is specified on the product label. For example, a solution concentration of 10 mg/mL means that 1 mL contains 10 mg of tirzepatide; if using an insulin syringe marked in units where 100 units equals 1 mL, then 10 units would deliver 1 mg. However, the FDA labels for Mounjaro describe pre-filled single-dose pens rather than multi-dose vials requiring user calculation, and dose selection is made by pen setting, not syringe measurement.
Compounded tirzepatide formulations may be supplied in vials at concentrations that differ from branded products, and the relationship between dose in milligrams and volume in units will depend on the compounding pharmacy's specification. A reader asking how many mg is 40 units of tirzepatide must first know the concentration of the solution in their possession; without that figure, the question cannot be answered. Any calculation of dose in units should be confirmed with the prescribing clinician or dispensing pharmacy to avoid under- or overdosing.
How Tirzepatide Doses Compare to Semaglutide
A 2024 systematic review and network meta-analysis in Diabetologia compared subcutaneously administered tirzepatide and semaglutide across 28 trials involving 23,622 participants. The analysis found that tirzepatide 15 mg was the most efficacious treatment in reducing HbA1c compared with placebo, while semaglutide 2.0 mg once weekly was less effective. For body weight reduction, the Annals of Internal Medicine review reported that semaglutide 2.4 mg once weekly resulted in weight loss of up to 13.9% after 68 weeks, compared with tirzepatide 15 mg at 17.8% after 72 weeks. Both agents share a similar adverse event profile, with gastrointestinal effects predominating.
The same Diabetologia review noted that tirzepatide's dual agonism of GIP and GLP-1 receptors distinguishes it mechanistically from semaglutide, which acts solely on GLP-1 receptors. According to the FDA label, tirzepatide selectively binds to and activates both receptor types, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner.
Tirzepatide Compound Dosage Considerations
Compounded tirzepatide refers to formulations prepared by a compounding pharmacy rather than manufactured as a branded product like Mounjaro or Zepbound. These formulations may be supplied at different concentrations and in multi-dose vials rather than pre-filled pens, requiring the user or clinician to calculate the volume corresponding to the intended dose in milligrams. The FDA labels provided do not address compounded preparations, and the clinical trial data cited in this guide were generated using commercial formulations at specified concentrations.
Readers using compounded tirzepatide should confirm the concentration of their specific formulation with the dispensing pharmacy and verify dose calculations with their prescribing clinician. Variability in compounding practices means that a dosage chart for one compounded product may not apply to another, and errors in unit-to-milligram conversion can result in significant under- or overdosing.
Documented Effects and Safety Profile Across Dose Ranges
The FDA label documents that tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes. At the 15 mg dose, tirzepatide reduced fasting glucagon concentration by 28% and glucagon area under the curve after a mixed meal by 43% compared with no change for placebo after 28 weeks of treatment. Tirzepatide also delays gastric emptying, with the delay largest after the first dose and diminishing over time.
A 2025 meta-analysis in Metabolism: Clinical and Experimental examined body composition changes and found that tirzepatide 15 mg weekly and semaglutide 2.4 mg weekly were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass. Lean mass loss comprised approximately 25% of total weight loss with GLP-1 receptor agonists, though relative lean mass as a percentage was unaffected. The same analysis noted that liraglutide at 3.0 mg weekly or 1.8 mg daily was the only GLP-1 receptor agonist to achieve significant weight reduction without significantly reducing lean mass.
Weight regain after discontinuation is proportional to the original weight loss, according to a 2025 systematic review in Obesity Reviews. Participants who took semaglutide or tirzepatide regained 9.69 kg after discontinuing therapy, compared with 2.20 kg for those who took liraglutide. This finding suggests that higher-potency agents associated with greater weight loss also carry a higher risk of regain when stopped.
Tirzepatide Calculator and Dose Conversion
A tirzepatide calculator typically refers to a tool for converting between dose in milligrams, solution concentration in mg/mL, and volume in milliliters or insulin syringe units. Such calculators are most relevant for users of compounded tirzepatide supplied in multi-dose vials rather than pre-filled pens. The calculation is straightforward: dose in mg divided by concentration in mg/mL equals volume in mL. To convert milliliters to insulin syringe units, multiply by 100, since a standard U-100 insulin syringe is marked such that 100 units equals 1 mL.
For example, if a compounded vial is labeled 10 mg/mL and the prescribed dose is 5 mg, the required volume is 0.5 mL, which corresponds to 50 units on a U-100 syringe. However, concentration varies by formulation, and users should verify the calculation with their pharmacist or clinician. The FDA-approved presentations of tirzepatide described in the Mounjaro label are pre-filled pens calibrated to deliver a set milligram dose per activation, eliminating the need for manual calculation.
This guide is general information compiled from published FDA labels, peer-reviewed trial reports, and systematic reviews. It is not medical advice. Decisions about tirzepatide dosing, escalation, and administration belong with a qualified clinician who can assess individual health status, comorbidities, and treatment goals.
